This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.

Background

A biopharmaceutical company had exclusively licensed a patent related to CAR-T therapy, a novel type of cancer immunotherapy that modifies a patient’s T cells to target and kill cancer more effectively. Its primary competitor had previously attempted to license and invalidate the patent, but failed at both. Despite being aware of potential infringement claims against its therapy, the competitor prioritized being first to market for its lead indication, attempting to lock in a sizeable portion of what was viewed to be a blockbuster marketplace. Upon its competitor achieving FDA approval, the company filed patent infringement claims against its competitor and its therapy.

Our Analysis

Intensity was called upon to evaluate the damages related to the alleged infringement. For this project, Intensity conducted economic analysis and provided trial testimony to determine reasonable royalties. This included an assessment of the economic contribution of the patented technology to the allegedly infringing product, availability of potential non-infringing alternatives, stage of development of licensed technology, competitive relationship between the two parties, financial harms and benefits from use of the patented technology by the alleged infringer, and market analysis of related license agreements. As part of its work, Intensity evaluated all fifteen of the Georgia-Pacific factors.

Intensity submitted an expert report and provided expert testimony at deposition and trial. After an eight-day trial, the jury returned a verdict in favor of Intensity’s client with a damages award that precisely matched the trial testimony.

Economic issues included: Apportionment; Discounted Cash Flow; Licensing; Reasonable Royalty; Valuation.